Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 117

Get the latest international news and world events from around the world.

Log in for authorized contributors

Why I Quit ChatGPT and Switched to Claude

“AI will most likely lead to the end of the world, but in the meantime there will be great companies created.” — Sam Altman, OpenAI CEO

I used to think that was dark humor.

This week, I stopped laughing — and cancelled my ChatGPT subscription.

Not because of the technology. Because of the values.

On February 27, Anthropic refused to give the Pentagon unrestricted access to its AI for mass surveillance and autonomous killer weapons. Within hours, OpenAI’s Sam Altman swooped in and took the deal.

One company held the line. The other sprinted to cross it.

Continue reading “Why I Quit ChatGPT and Switched to Claude” | >

Australian consortium to develop quantum biotechnology platform to transform Alzheimer’s treatment discovery

“Our system provides a pathway towards a fast, scalable tool for measuring real-time brain activity in synthetic tissue cultures that replicate human brain tissue,” Associate Professor Simpson said.

If successful, this brain-on-chip technology could help evaluate the effectiveness of treatments for neurological diseases, including Alzheimer’s, schizophrenia, epilepsy and anxiety, in the laboratory before moving into expensive and complex human trials.

Scientists just turned light into a remote control for crystals

NYU researchers have found a way to use light to control how microscopic particles assemble into crystals, effectively turning illumination into a tool for shaping matter. By adding light-sensitive molecules to a liquid filled with tiny particles, they can adjust how strongly the particles attract or repel one another simply by changing the light’s intensity or pattern. This allows them to trigger crystals to form, dissolve, or even be reshaped in real time.

‘An AlphaFold 4’ — scientists marvel at DeepMind drug spin-off’s exclusive new AI

Isomorphic Labs has developed a drug-protein interaction model which surpasses the previous tech in this area. Yet the model is proprietary, so no one knows how it was designed and trained and why it works so well!

Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left guessing how to achieve similar results.

DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer

Breast cancer destroyed by a plant compound.

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the poorest prognosis, and poses a significant threat to women’s health. In this study, we identified two novel prieurianin-type limonoids extracted from Munronia henryi, one of which, named DHL-11, exhibited antitumor activity against TNBC cells. DHL-11 suppressed cell proliferation and migration, induced G2/M cell cycle arrest and apoptosis, and effectively increased the accumulation of reactive oxygen species (ROS) and cellular DNA damage in TNBC cells. Mechanistically, we found that DHL-11 binds to the non-catalytic pocket of IMPDH2 and disrupts the interaction between IMPDH2 and FANCI, leading to the degradation of the IMPDH2 protein. The decrease of IMPDH2 protein reduced guanine synthesis, increased ROS levels, and induced DNA damage.

Tiny Blood Smidges in the Brain: Amount and Location Tied to Dementia

Ploidy and neuron size impact nervous system development and function in Xenopus.

Liu et al. use triploid Xenopus as a model to characterize effects of neuron size on vertebrate nervous system development and function. They report association between neuron size, cell proliferation, brain activity, and tadpole swimming behavior.

Proton therapy for colorectal cancer

SA-CME credits are available for this article here.

Ever since the first proton beam therapy (PBT) treatment in 1954 at University of California, Berkley, the use of PBT worldwide has rapidly increased.1 Due to the depth-dose characteristics of protons that allow for steep fall-off just distal to the tumor target, PBT can reduce unnecessary radiation dose to nearby normal tissues and allow for safer dose escalation in select clinical scenarios. Superior normal tissue avoidance can lead to reductions in acute and late toxicities, safe dose escalation can lead to improved local control, and the combination of both factors has the potential to impact overall survival (OS).

Early data have suggested that PBT led to improved clinical outcomes in the treatment of various pediatric cancers, ocular melanomas, sarcomas of the paravertebral region, and brain tumors when compared with traditional photon-based radiation.2 Historically, fewer studies evaluated the utility of PBT in the treatment of gastrointestinal (GI) malignancies; however, retrospective studies in the setting of gastroesophageal cancer and pancreatic cancer show that preoperative PBT may reduce postoperative complications and definitive PBT may improve outcomes for those with unresectable disease.3–6 Even fewer studies have evaluated the role of PBT in the primary or neoadjuvant treatment of colorectal cancer (CRC), but there have been published clinical outcomes in the treatment of recurrent disease as well as liver metastases. The aim of this review is to discuss the existing dosimetric and clinical data for PBT in the treatment of patients with CRC.

/* */